Pharmaniaga Berhad Future Growth

Future criteria checks 3/6

Pharmaniaga Berhad is forecast to grow earnings and revenue by 109.9% and 1.4% per annum respectively while EPS is expected to grow by 111.1% per annum.

Key information

109.9%

Earnings growth rate

111.1%

EPS growth rate

Healthcare earnings growth-9.0%
Revenue growth rate1.4%
Future return on equityn/a
Analyst coverage

Low

Last updated01 Mar 2024

Recent future growth updates

Recent updates

Pharmaniaga Berhad (KLSE:PHARMA) Shares Could Be 49% Below Their Intrinsic Value Estimate

Apr 19
Pharmaniaga Berhad (KLSE:PHARMA) Shares Could Be 49% Below Their Intrinsic Value Estimate

Insufficient Growth At Pharmaniaga Berhad (KLSE:PHARMA) Hampers Share Price

Oct 03
Insufficient Growth At Pharmaniaga Berhad (KLSE:PHARMA) Hampers Share Price

Is There An Opportunity With Pharmaniaga Berhad's (KLSE:PHARMA) 37% Undervaluation?

Jul 19
Is There An Opportunity With Pharmaniaga Berhad's (KLSE:PHARMA) 37% Undervaluation?

Is It Too Late To Consider Buying Pharmaniaga Berhad (KLSE:PHARMA)?

Feb 18
Is It Too Late To Consider Buying Pharmaniaga Berhad (KLSE:PHARMA)?

Many Would Be Envious Of Pharmaniaga Berhad's (KLSE:PHARMA) Excellent Returns On Capital

Dec 10
Many Would Be Envious Of Pharmaniaga Berhad's (KLSE:PHARMA) Excellent Returns On Capital

Bullish: Analysts Just Made A Massive Upgrade To Their Pharmaniaga Berhad (KLSE:PHARMA) Forecasts

Nov 24
Bullish: Analysts Just Made A Massive Upgrade To Their Pharmaniaga Berhad (KLSE:PHARMA) Forecasts

We Think That There Are Issues Underlying Pharmaniaga Berhad's (KLSE:PHARMA) Earnings

Aug 27
We Think That There Are Issues Underlying Pharmaniaga Berhad's (KLSE:PHARMA) Earnings

Pharmaniaga Berhad (KLSE:PHARMA) Has A Somewhat Strained Balance Sheet

May 28
Pharmaniaga Berhad (KLSE:PHARMA) Has A Somewhat Strained Balance Sheet

Should You Buy Pharmaniaga Berhad (KLSE:PHARMA) For Its 1.8% Dividend?

Mar 15
Should You Buy Pharmaniaga Berhad (KLSE:PHARMA) For Its 1.8% Dividend?

Earnings and Revenue Growth Forecasts

KLSE:PHARMA - Analysts future estimates and past financials data (MYR Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/20253,50346N/AN/A1
12/31/20243,3364523831
12/31/20233,404-77-1546N/A
9/30/20233,507-667-76-15N/A
6/30/20233,517-631-2237N/A
3/31/20233,429-632-278-218N/A
12/31/20223,511-607-220-142N/A
9/30/20223,330100-186-105N/A
6/30/20224,568164145214N/A
3/31/20224,984177-2432N/A
12/31/20214,815172-109-64N/A
9/30/20214,73880-237N/A
6/30/20213,23032-394-356N/A
3/31/20212,69928-69-30N/A
12/31/20202,72527-58-26N/A
9/30/20202,806-145044N/A
6/30/20202,898-14648111N/A
3/31/20202,854-146-2146N/A
12/31/20192,821-149117190N/A
9/30/20192,70134108176N/A
6/30/20192,5724833106N/A
3/31/20192,55344100181N/A
12/31/20182,38542-154-82N/A
9/30/20182,40260-122-42N/A
6/30/20182,38848-80-20N/A
3/31/20182,32452-76-12N/A
12/31/20172,32454161239N/A
9/30/20172,29431N/A209N/A
6/30/20172,23441N/A231N/A
3/31/20172,24846N/A218N/A
12/31/20162,18946N/A35N/A
9/30/20162,28662N/A50N/A
6/30/20162,29669N/A54N/A
3/31/20162,27771N/A1N/A
12/31/20152,18984N/A7N/A
9/30/20152,136105N/A17N/A
6/30/20152,114100N/A52N/A
3/31/20152,12699N/A95N/A
12/31/20142,12394N/A213N/A
9/30/20142,06478N/A170N/A
6/30/20142,00267N/A140N/A
3/31/20141,91557N/A206N/A
12/31/20131,94755N/A255N/A
9/30/20131,86126N/A161N/A
6/30/20131,84748N/A115N/A
3/31/20131,86658N/A62N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: PHARMA is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (3.5%).

Earnings vs Market: PHARMA is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: PHARMA is expected to become profitable in the next 3 years.

Revenue vs Market: PHARMA's revenue (1.4% per year) is forecast to grow slower than the MY market (5.7% per year).

High Growth Revenue: PHARMA's revenue (1.4% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if PHARMA's Return on Equity is forecast to be high in 3 years time


Discover growth companies

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.